Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an adverse effect on the structure or function of the central and/or peripheral nervous system. It occurs when exposure to a substance – specifically, a neurotoxin or neurotoxicant– alters the normal activity of the nervous system in such a way as to cause permanent or reversible damage to nervous tissue. This can eventually disrupt or even kill neurons, which are cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from organ transplants, radiation treatment, certain drug therapies, recreational drug use, and exposure to heavy metals, bites from certain species of venomous snakes, pesticides, certain industrial cleaning solvents, fuels and certain naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness, loss of memory, vision, and/or intellect, uncontrollable obsessive and/or compulsive behaviors, delusions, headache, cognitive and behavioral problems and sexual dysfunction. Chronic mold exposure in homes can lead to neurotoxicity which may not appear for months to years of exposure. All symptoms listed above are consistent with mold mycotoxin accumulation.
The term neurotoxicity implies the involvement of a neurotoxin; however, the term neurotoxic may be used more loosely to describe states that are known to cause physical brain damage, but where no specific neurotoxin has been identified.
The presence of neurocognitive deficits alone is not usually considered sufficient evidence of neurotoxicity, as many substances may impair neurocognitive performance without resulting in the death of neurons. This may be due to the direct action of the substance, with the impairment and neurocognitive deficits being temporary, and resolving when the substance is eliminated from the body. In some cases the level or exposure-time may be critical, with some substances only becoming neurotoxic in certain doses or time periods. Some of the most common naturally occurring brain toxins that lead to neurotoxicity as a result of long term drug use are beta amyloid (Aβ), glutamate, dopamine, and oxygen radicals. When present in high concentrations, they can lead to neurotoxicity and death (apoptosis). Some of the symptoms that result from cell death include loss of motor control, cognitive deterioration and autonomic nervous system dysfunction. Additionally, neurotoxicity has been found to be a major cause of neurodegenerative diseases such as Alzheimer's disease (AD).
Aβ was found to cause neurotoxicity and cell death in the brain when present in high concentrations. Aβ results from a mutation that occurs when protein chains are cut at the wrong locations, resulting in chains of different lengths that are unusable. Thus they are left in the brain until they are broken down, but if enough accumulate, they form plaques which are toxic to neurons. Aβ uses several routes in the central nervous system to cause cell death. An example is through the nicotinic acetylcholine receptor (nAchRs), which is a receptor commonly found along the surfaces of the cells that respond to nicotine stimulation, turning them on or off. Aβ was found manipulating the level of nicotine in the brain along with the MAP kinase, another signaling receptor, to cause cell death. Another chemical in the brain that Aβ regulates is JNK; this chemical halts the extracellular signal-regulated kinases (ERK) pathway, which normally functions as memory control in the brain. As a result, this memory favoring pathway is stopped, and the brain loses essential memory function. The loss of memory is a symptom of neurodegenerative disease, including AD. Another way Aβ causes cell death is through the phosphorylation of AKT; this occurs as the element phosphate is bound to several sites on the protein. This phosphorylation allows AKT to interact with BAD, a protein known to cause cell death. Thus an increase in Aβ results in an increase of the AKT/BAD complex, in turn stopping the action of the anti-apoptotic protein Bcl-2, which normally functions to stop cell death, causing accelerated neuron breakdown and the progression of AD.
Glutamate is a chemical found in the brain that poses a toxic threat to neurons when found in high concentrations. This concentration equilibrium is extremely delicate and is usually found in millimolar amounts extracellularly. When disturbed, an accumulation of glutamate occurs as a result of a mutation in the glutamate transporters, which act like pumps to drain glutamate from the brain. This causes glutamate concentration to be several times higher in the blood than in the brain; in turn, the body must act to maintain equilibrium between the two concentrations by pumping the glutamate out of the bloodstream and into the neurons of the brain. In the event of a mutation, the glutamate transporters are unable to pump the glutamate back into the cells; thus a higher concentration accumulates at the glutamate receptors. This opens the ion channels, allowing calcium to enter the cell causing excitotoxicity. Glutamate results in cell death by turning on the N-methyl-D-aspartic acid receptors (NMDA); these receptors cause an increased release of calcium ions (Ca2+) into the cells. As a result, the increased concentration of Ca2+ directly increases the stress on mitochondria, resulting in excessive oxidative phosphorylation and production of reactive oxygen species (ROS) via the activation of nitric oxide synthase, ultimately leading to cell death. Aβ was also found aiding this route to neurotoxicity by enhancing neuron vulnerability to glutamate.
The formation of oxygen radicals in the brain is achieved through the nitric oxide synthase (NOS) pathway. This reaction occurs as a response to an increase in the Ca2+ concentration inside a brain cell. This interaction between the Ca2+ and NOS results in the formation of the cofactor tetrahydrobiopterin (BH4), which then moves from the plasma membrane into the cytoplasm. As a final step, NOS is dephosphorylated yielding nitric oxide (NO), which accumulates in the brain, increasing its oxidative stress. There are several ROS, including superoxide, hydrogen peroxide and hydroxyl, all of which lead to neurotoxicity. Naturally, the body utilizes a defensive mechanism to diminish the fatal effects of the reactive species by employing certain enzymes to break down the ROS into small, benign molecules of simple oxygen and water. However, this breakdown of the ROS is not completely efficient; some reactive residues are left in the brain to accumulate, contributing to neurotoxicity and cell death. The brain is more vulnerable to oxidative stress than other organs, due to its low oxidative capacity. Because neurons are characterized as postmitotic cells, meaning that they live with accumulated damage over the years, accumulation of ROS is fatal. Thus, increased levels of ROS age neurons, which leads to accelerated neurodegenerative processes and ultimately the advancement of AD.
Certain drugs, most famously the pesticide and metabolite MPP+ (1-methyl-4-phenylpyridin-1-ium) can induce Parkinson's disease by destroying dopaminergic neurons in the substantia nigra. MPP+ interacts with the electron transport chain in the mitochondria to generate reactive oxygen species which cause generalized oxidative damage and ultimately cell death. MPP+ is produced by monoamine oxidase B as a metabolite of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), and its toxicity is particularly significant to dopaminergic neurons because of an active transporter on those cells that bring it into the cytoplasm. The neurotoxicity of MPP+ was first investigated after MPTP was produced as a contaminant in the pethidine synthesized by a chemistry graduate student, who injected the contaminated drug and developed overt Parkinson's within weeks. Discovery of the mechanism of toxicity was an important advance in the study of Parkinson's disease, and the compound is now used to induce the disease in research animals.
The prognosis depends upon the length and degree of exposure and the severity of neurological injury. In some instances, exposure to neurotoxins or neurotoxicants can be fatal. In others, patients may survive but not fully recover. In other situations, many individuals recover completely after treatment.
- Cunha-Oliveira, Teresa; Rego, Ana Cristina; Oliveira, Catarina R. (June 2008). "Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs". Brain Research Reviews. 58 (1): 192–208. doi:10.1016/j.brainresrev.2008.03.002. hdl:10316/4676. PMID 18440072. S2CID 17447665.
- Keifer, Matthew C.; Firestone, Jordan (31 July 2007). "Neurotoxicity of Pesticides". Journal of Agromedicine. 12 (1): 17–25. doi:10.1300/J096v12n01_03. PMID 18032333. S2CID 23069667.
- Costa, Lucio, G.; Giordano, G; Guizzetti, M; Vitalone, A (2008). "Neurotoxicity of pesticides: a brief review". Frontiers in Bioscience. 13 (13): 1240–9. doi:10.2741/2758. PMID 17981626. S2CID 36137987.
- Sainio, Markku Alarik (2015). "Neurotoxicity of solvents". Occupational Neurology. Handbook of Clinical Neurology. 131. pp. 93–110. doi:10.1016/B978-0-444-62627-1.00007-X. ISBN 978-0-444-62627-1. PMID 26563785.
- Ritchie, Glenn D.; Still, Kenneth R.; Alexander, William K.; Nordholm, Alan F.; Wilson, Cody L.; Rossi III, John; Mattie, David R. (1 July 2001). "A review of the neurotoxicity risk of selected hydrocarbon fuels". Journal of Toxicology and Environmental Health Part B: Critical Reviews. 4 (3): 223–312. doi:10.1080/109374001301419728. PMID 11503417.
- Curtis, Luke; Lieberman, Allan; Stark, Martha; Rea, William; Vetter, Marsha (September 2004). "Adverse Health Effects of Indoor Molds". Journal of Nutritional & Environmental Medicine. 14 (3): 261–274. doi:10.1080/13590840400010318.
- Kilburn, Kaye H. (2004). Role of Molds and Mycotoxins in Being Sick in Buildings: Neurobehavioral and Pulmonary Impairment. Advances in Applied Microbiology. 55. pp. 339–359. doi:10.1016/S0065-2164(04)55013-X. ISBN 978-0-12-002657-9. PMID 15350801.
- edited by Stewart A. Factor, William J. Weiner (2008). Parkinson's disease : diagnosis and clinical management (2 ed.). New York: Demos. ISBN 978-1-934559-87-1. OCLC 191726483.CS1 maint: extra text: authors list (link)
- Langston, J. W. (1995). The case of the frozen addicts. Jon Palfreman (1 ed.). New York: Pantheon Books. ISBN 0-679-42465-2. OCLC 31608154.
- Jackson-Lewis, Vernice; Przedborski, Serge (Jan 2007). "Protocol for the MPTP mouse model of Parkinson's disease". Nature Protocols. 2 (1): 141–151. doi:10.1038/nprot.2006.342. ISSN 1750-2799. PMID 17401348. S2CID 39743261.
- Fahn, Stanley (1996-12-26). "Book Review". New England Journal of Medicine. 335 (26): 2002–2003. doi:10.1056/NEJM199612263352618. ISSN 0028-4793.
- National Research Council (1992). Environmental Neurotoxicology. ISBN 978-0-309-04531-5.[page needed]
|Scholia has a profile for neurotoxicity (Q3338704).|
- Akaike, Akinori; Takada-Takatori, Yuki; Kume, Toshiaki; Izumi, Yasuhiko (January 2010). "Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in Neuroprotection". Journal of Molecular Neuroscience. 40 (1–2): 211–216. doi:10.1007/s12031-009-9236-1. PMID 19714494. S2CID 7279060.
- Buckingham, Steven D.; Jones, Andrew K.; Brown, Laurence A.; Sattelle, David B. (March 2009). "Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection". Pharmacological Reviews. 61 (1): 39–61. doi:10.1124/pr.108.000562. PMC 2830120. PMID 19293145.
- Huber, Anke; Stuchbury, Grant; Burkle, Alexander; Burnell, Jim; Munch, Gerald (1 February 2006). "Neuroprotective Therapies for Alzheimers Disease". Current Pharmaceutical Design. 12 (6): 705–717. doi:10.2174/138161206775474251. PMID 16472161.
- Takada-Takatori, Yuki; Kume, Toshiaki; Izumi, Yasuhiko; Ohgi, Yuta; Niidome, Tetsuhiro; Fujii, Takeshi; Sugimoto, Hachiro; Akaike, Akinori (2009). "Roles of Nicotinic Receptors in Acetylcholinesterase Inhibitor-Induced Neuroprotection and Nicotinic Receptor Up-Regulation". Biological & Pharmaceutical Bulletin. 32 (3): 318–324. doi:10.1248/bpb.32.318. PMID 19252271.
- Takada-Takatori, Yuki; Kume, Toshiaki; Sugimoto, Mitsuhiro; Katsuki, Hiroshi; Sugimoto, Hachiro; Akaike, Akinori (September 2006). "Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade". Neuropharmacology. 51 (3): 474–486. doi:10.1016/j.neuropharm.2006.04.007. PMID 16762377. S2CID 31409248.
- Shimohama, Shun (2009). "Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models". Biological & Pharmaceutical Bulletin. 32 (3): 332–336. doi:10.1248/bpb.32.332. PMID 19252273.
- Ryan, Melody; Kennedy, Kara A. (2009). "Neurotoxic Effects of Pharmaceutical Agents II: Psychiatric Agents". Clinical Neurotoxicology. pp. 348–357. doi:10.1016/B978-032305260-3.50037-X. ISBN 978-0-323-05260-3.
- Lerner, David P.; Tadevosyan, Aleksey; Burns, Joseph D. (1 November 2020). "Toxin-Induced Subacute Encephalopathy". Neurologic Clinics. 38 (4): 799–824. doi:10.1016/j.ncl.2020.07.006. PMID 33040862. S2CID 222301922.